复发难治外周T细胞淋巴瘤治疗进展  

Treatment progress of relapsed/refractory peripheral T-cell lymphoma

作　　者：陈静[1] 赵毅[1] Chen Jing;Zhao Yi(Bone Marrow Transplantation Center,the First Afiliated Hospital of Zhejiang University School of Medicine,Hangzhou310003,China)

机构地区：[1]浙江大学医学院附属第一医院骨髓移植中心,杭州310003

出　　处：《白血病．淋巴瘤》2022年第10期634-637,共4页Journal of Leukemia & Lymphoma

基　　金：中华医学会医学教育分会和中国高等教育学会医学教育专业委员会2020年医学教育研究课题(20B0985);浙江省自然科学基金(LY22H080004)。

摘　　要：外周T细胞淋巴瘤(PTCL)是一组起源于胸腺后T细胞或成熟自然杀伤(NK)细胞的异质性疾病。随着医疗技术的革新,PTCL患者的预后明显改善,但是仍有一部分患者出现复发、难治、预后较差的情况。近年来,二线化疗方案、造血干细胞移植、部分新药(组蛋白去乙酰化酶抑制剂、二氢叶酸还原酶抑制剂、极光激酶A抑制剂、磷脂酰肌醇3-激酶抑制剂、靶向治疗等)的应用在复发难治PTCL患者的治疗中发挥着重要作用,同时,移植方案的选择及以新药为骨架的方案之间的联合也成为研究的热点。Peripheral T-cell lymphoma (PTCL) is a group of heterogeneous diseases originating from retrothymic T lymphocytes or mature natural killer (NK) cells. With the innovation of medical technology, the prognosis of patients with PTCL has been greatly improved. However, there are still some patients who are refractory or relapsed after treatment and have poor prognosis. In recent years, the applications of second-line chemotherapy regimen, hematopoietic stem cell transplantation and several new drugs (histone deacetylase inhibitors, dihydrofolate reductase inhibitors, aurora A kinase inhibitors, phosphatidylinositol 3-kinase inhibitors, targeted therapy, etc.) have played an important role in the treatment of relapsed/refractory PTCL patients. Meanwhile, the choice of transplantation programs and the combination of new drug-based schemes have also become research hotspots.

关 键 词：淋巴瘤 T细胞 外周复发难治肿瘤治疗方案 

分 类 号：R733[医药卫生—肿瘤]